» Articles » PMID: 29242356

Pre-treatment Growth and IGF-I Deficiency As Main Predictors of Response to Growth Hormone Therapy in Neural Models

Overview
Journal Endocr Connect
Specialty Endocrinology
Date 2017 Dec 16
PMID 29242356
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Mathematical models have been applied in prediction of growth hormone treatment effectiveness in children since the end of 1990s. Usually they were multiple linear regression models; however, there are also examples derived by empirical non-linear methods. Proposed solution consists in application of machine learning technique - artificial neural networks - to analyse this problem. This new methodology, contrary to previous ones, allows detection of both linear and non-linear dependencies without assuming their character The aims of this work included: development of models predicting separately growth during 1st year of treatment and final height as well as identification of important predictors and in-depth analysis of their influence on treatment's effectiveness. The models were derived on the basis of clinical data of 272 patients treated for at least 1 year, 133 of whom have already attained final height. Starting from models containing 17 and 20 potential predictors, respectively for 1st year and final height model, we were able to reduce their number to 9 and 10. Basing on the final models, IGF-I concentration and earlier growth were indicated as belonging to most important predictors of response to GH therapy, while results of GH secretion tests were automatically excluded as insignificant. Moreover, majority of the dependencies were observed to be non-linear, thus using neural networks seems to be reasonable approach despite it being more complex than previously applied methods.

Citing Articles

Extending curve matching with flexible hyperparameter selection to predict response to long-acting PEGylated growth hormone treatment in growth hormone deficiency children: method development and validation.

Hou L, Fu J, Wei H, Liang L, Du H, Zhang J J Endocrinol Invest. 2025; .

PMID: 39969796 DOI: 10.1007/s40618-025-02546-z.


Transient Isolated, Idiopathic Growth Hormone Deficiency-A Self-Limiting Pediatric Disease with Male Predominance or a Diagnosis Based on Uncertain Criteria? Lesson from 20 Years' Real-World Experience with Retesting at One Center.

Smyczynska J, Hilczer M, Smyczynska U, Lewinski A, Stawerska R Int J Mol Sci. 2024; 25(11).

PMID: 38891927 PMC: 11171613. DOI: 10.3390/ijms25115739.


Curve matching to predict growth in patients receiving growth hormone therapy: An interpretable & explainable method.

van Dommelen P, Arnaud L, Koledova E Front Endocrinol (Lausanne). 2022; 13:999077.

PMID: 36277722 PMC: 9579689. DOI: 10.3389/fendo.2022.999077.


Isolated childhood growth hormone deficiency: a 30-year experience on final height and a new prediction model.

Lonero A, Giotta M, Guerrini G, Calcaterra V, Galazzi E, Iughetti L J Endocrinol Invest. 2022; 45(9):1709-1717.

PMID: 35567736 DOI: 10.1007/s40618-022-01808-4.


An eHealth Framework for Managing Pediatric Growth Disorders and Growth Hormone Therapy.

Dimitri P, Fernandez-Luque L, Banerjee I, Bergada I, Calliari L, Dahlgren J J Med Internet Res. 2021; 23(5):e27446.

PMID: 34014174 PMC: 8176345. DOI: 10.2196/27446.


References
1.
Dahlgren J, Kristrom B, Niklasson A, Nierop A, Rosberg S, Albertsson-Wikland K . Models predicting the growth response to growth hormone treatment in short children independent of GH status, birth size and gestational age. BMC Med Inform Decis Mak. 2007; 7:40. PMC: 2246105. DOI: 10.1186/1472-6947-7-40. View

2.
Ranke M, Lindberg A, Price D, Darendeliler F, Albertsson-Wikland K, Wilton P . Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Horm Res. 2007; 68(2):53-62. DOI: 10.1159/000098707. View

3.
Ranke M, Lindberg A, Martin D, Bakker B, Wilton P, Albertsson-Wikland K . The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH dose. J Clin Endocrinol Metab. 2003; 88(10):4748-53. DOI: 10.1210/jc.2003-030600. View

4.
Wikland K, Kristrom B, Rosberg S, Svensson B, Nierop A . Validated multivariate models predicting the growth response to GH treatment in individual short children with a broad range in GH secretion capacities. Pediatr Res. 2000; 48(4):475-84. DOI: 10.1203/00006450-200010000-00010. View

5.
Wit J, Ranke M, Albertsson-Wikland K, Carrascosa A, Rosenfeld R, Buuren S . Personalized approach to growth hormone treatment: clinical use of growth prediction models. Horm Res Paediatr. 2013; 79(5):257-70. DOI: 10.1159/000351025. View